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Urinary incontinence affects approximately a quarter of a billion people worldwide. It is associated with high economic costs, 
psychological morbidity and adverse effects on the quality of life.  Despite this, few women seek help for this condition either 
due to embarrassment and unwillingness to discuss the symptom with their family member or friend or, acceptance of the 
disorder as a natural part of aging or being unaware that treatment exists.  More resources are utilised in maintaining patients 
with chronic incontinence rather than for diagnosis and treatment of the condition. Urinary incontinence is a complex problem 
resulting from many different causes and for which many different approaches to treatment exist. The commonest types of in-
continence include stress urinary incontinence, urge urinary incontinence and mixed incontinence.
Recently, better understanding of the pathophysiology of urinary incontinence has led to the development of numerous non-
pharmacological, pharmacological and surgical interventions.
Introduction
According to the World Health Organi-
sation, urinary incontinence is “a wide-
spread global disease and one of the 
last medical taboos for many people”.2 
In South Africa, urinary incontinence 
and pelvic floor dysfunction are major 
health problems. Urinary incontinence 
affects all ages, both sexes, and all 
social classes. Its prevalence is under-
estimated and it is estimated that only 
one in four symptomatic women will 
seek help for this problem.3 The annual 
direct cost in all ages for incontinence is 
estimated to be over16 billion US dollars 
(in 1995 dollars), which is more than that 
of breast, cervical, ovarian and uterine 
cancers combined.4,5
In 2002, the Standardisation Sub-
committee of the International Con-
tinence Society (ICS) changed the 
original ICS definition of incontinence, 
from ‘urinary incontinence is the invol-
untary loss of urine that is a social or 
hygienic problem,’ since it relates the 
complaint to the quality of life, to ‘urinary 
incontinence is the complaint of any in-
voluntary loss of urine’.6 Standardisation 
thus facilitates comparison of results 
and effective communication between 
clinicians.
Types of Urinary Incontinence
There are three main types of urinary 
incontinence (UI), stress urinary incon-
tinence, urge urinary incontinence and 
mixed urinary incontinence.
According to the ICS, the definitions are 
as follows:
•  Stress UI is the complaint of involun-
tary leakage on effort or exertion, or 
on sneezing or coughing.
•  Urge UI is the complaint of involun-
tary leakage accompanied by or im-
mediately preceded by urgency (a 
sudden compelling desire to urinate 
that is difficult to defer).
•  Mixed UI is the complaint of invol-
untary leakage associated with ur-
gency and also with exertion, effort, 
sneezing or coughing.
Stress UI (SUI) is a very common con-
dition affecting approximately half of 
incontinent women between 18 and 90 
years of age. In stress UI there are two 
main mechanisms for urinary leakage:
•  Insufficient urethral support from the 
endopelvic fascia and muscles. Pe-
riods of increased intra-abdominal 
pressure causes descent of the ure-
thra-vesical junction. Increased ure-
thral mobility forces urine from the 
bladder into the urethra
•  Intrinsic sphincter deficiency (ISD) 
occurs when there is failure of the 
urethral sphincter due to mucosal 
and muscular atrophy and denerva-
tion, occurring alone or in combina-
tion with inadequate urethral support. 
It is commonly due to aging, neuro-
logic disorders, obstetric/surgical 
trauma and lack of estrogen.
Urge incontinence, together with other 
symptoms such as urgency, frequency, 
and nocturia forms part of the overactive 
bladder (OAB) symptom syndrome. Ur-
gency is the ‘driving’ symptom in OAB, 
with the patient experiencing urgency at 
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Figure 1: Urgency drives the other symptoms of the overactive bladder syndrome.
Adapted from Chapple, et al. The role of urinary urgency and its measurement in the 
overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 
2005; 95: 335-340.7
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unpredictable and inconvenient times 
resulting in the loss of urine before the 
toilet can be reached.7 (See Figure 
1). The overall prevalence of OAB is 
estimated to be 16,9% in the United 
States, the prevalence increasing with 
advancing age.8 Incontinence occurs 
in approximately one third of  patients 
presenting clinically with OAB. 
Recently a cross-sectional population 
based survey of 11521 individuals aged 
40- 64 years, conducted in France, 
Germany, Italy, Spain, Sweden and 
the United Kingdom concluded that 
the OAB symptoms have a significant 
effect on the emotional well-being and 
productivity of the patient both at home 
and at work.9
Mixed urinary incontinence, a combi-
nation of both stress and urge inconti-
nence, may result from compensatory 
responses initiated by the incontinent 
patient. Approximately 50% of patients 
with incontinence will have mixed uri-
nary incontinence symptoms. The de-
gree to which each component contrib-
utes to the patient’s incontinence varies, 
but one symptom will be dominant either 
stress or urgency.
Initial Assessment
In the initial assessment, the patient’s 
incontinence should be categorised, 
and treatment tailored toward the pre-
dominant symptom.
To achieve optimum success, good 
communication between the healthcare 
professional and patient is imperative. 
According to the National Institute of 
Clinical Excellence (NICE) Clinical 
Guideline, healthcare professionals 
should adopt a ‘women-centered care’ 
approach women should be provided 
with evidence based information and 
the treatment and care tailored to their 
individual needs and preferences.10
During examination a routine digi-
tal assessment of pelvic floor muscle 
contraction should be done, using the 
Oxford grading system. The grade, 
strength and duration of muscle con-
traction is assessed. The scale is as 
follows:







The Q-tip test evaluates the mobility of 
the urethra and bladder neck. This is 
done by inserting a sterile, lubricated 
cotton-bud into the urethra to the level 
of the bladder neck. The patient is then 
asked to strain. The resting and strain-
ing angles are measured, and the 
difference between the two angles is 
calculated. A difference of greater than 
30 degrees is thought to be indicative of 
hypermobile urethra.  Note that this test 
does not establish the diagnosis of SUI 
and does not add any extra information 
to history and examination.11, 12
The Bonney test is a test of blad-
der neck elevation and indicates the 
likelihood of curing stress incontinence 
with a vaginal repair. It is currently not 
recommended for testing urethral com-
petence. To demonstrate SUI the patient 
should have a full bladder. Note that of-
ten women will empty their bladder prior 
to a gynaecologic examination.
After history and examination, a urine 
dipstick test should be done to exclude 
a urinary tract infection. Urine positive 
for leucocytes and nitrites should be 
sent for microscopy, culture and sen-
sitivity. A post-void residual should be 
done either by a bladder scan or by 
catheterisation.
This should be followed by a 3 day 
bladder diary, incorporating both a 
working and a leisure day. Bladder 
diaries are a reliable method of quantify-
ing urinary frequency and incontinence 
episodes.
Identify factors warranting urgent refer-
ral i.e.: 
•  Microscopic haematuria if aged 50 
years and older
• Visible haematuria
•  Recurrent or persisting UTI associ-
ated with haematuria if aged 40 years 
and  older
•  Suspected pelvic mass arising from 
the urinary tract.
Categorise the urinary incontinence and 
discuss treatment options with patient, 
family or carer.
The use of multi-channel cystometry, 
ambulatory urodynamics or video-uro-
dynamics is not recommended before 
starting conservative treatment. It is 
recommended in women before surgery 
for UI if:
•  There is clinical suspicion of overac-
tive bladder, or
•  There has been previous surgery for 
stress incontinence or an anterior 
compartment prolapse, or
•  There are symptoms suggestive of 
voiding dysfunction. 
It has not been shown that carrying out 




This includes the following:
In patients with urge UI/ OAB:
• Reduction in caffeine consumption
•  Fluid restriction to 2 - 2,5 liters per 
24 hour
•  Reduction of body mass index to ≤ 30
Physical therapy
In patients with mild SUI or mixed UI, a 
trial of supervised pelvic floor muscle 
training of at least three month’s dura-
tion should be offered as first line treat-
ment. Evidence suggests that pelvic 
muscle floor training continued for three 
months is safe and effective.
Pelvic floor muscle training should be 
offered to women in their first pregnancy 
as a preventative strategy for UI, since it 
reduces the likelihood of postnatal UI.
Therapy should comprise at least eight 
contractions three times day. Electrical 
stimulation and/or biofeedback should 
be considered when women do not ac-
tively contract their pelvic floor muscles, 
thereby promoting motivation.
In patients with urge or mixed UI, 
bladder training for a minimum of 6 
weeks should be offered as first line 
treatment. Bladder training has fewer 
adverse effects and lower relapse rates 
than treatment with anti-muscarinic 
agents. The addition of an anti-musca-
rinic agent should be considered should 
one not achieve benefit from bladder 
training alone.
DRUG THERAPY
Although the mainstay of treatment for 
SUI is surgical treatment, new drug 
therapies are being sought worldwide. 
Attention has focused on alpha-ago-
nists with a high specificity for urethral 
smooth muscle and selective serotonin 
norepinephrine reuptake inhibitors, spe-
cifically duloxetine. 
Duloxetine inhibits the reuptake of 
serotonin and norepinephrine in the 
motor neurons of the pudendal nerve. 
This increases the amount of neu-
rotransmitters in the sacral spinal cord 
(Onuf’s nucleus), the end result being 
increased pudendal stimulation of the 
urethral striated sphincter muscle. It has 
been shown to significantly improve the 
incontinence episode frequency and 
quality of life in patients with SUI.13 Nau-
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sea is the most common adverse effect 
which may result in discontinuation of 
treatment. Other side-effects include 
fatigue, dry mouth, insomnia, constipa-
tion, dizziness and somnolence. It is, 
however, not recommended as first-line 
treatment. It may be offered as second-
line treatment when:
•  Women prefer pharmacological 
treatment to surgical treatment
•  Women not suitable for surgical 
treatment
Drug therapy is the mainstay of treat-
ment for overactive bladder. Most of the 
drugs exert their effects by acting on 
the acetylcholine receptors within the 
detrusor muscle. These are not without 
side-effects and therefore therapy is 
seldom continued indefinitely. Among 
the list below, oxybutynin has a well 
documented efficacy and is becoming 
more widely available with new and 
novel delivery systems. Oxybutynin 
and tolterodine are currently the firstline 
treatment for patients with overactive 
bladder. Table 2 below compares the 
different drugs used in the treatment of 
overactive bladder.
SURGICAL TREATMENT
When conservative management has 
failed, a detailed discussion of benefits 
versus risks of surgical treatment is the 
first step.
Stress UI:
The retropubic mid-urethral tape (bot-
tom-up approach), with a type 1 mesh 
(acroporous polypropylene with pore 
size > 50µm) is the procedure of choice 
due to the efficacy of long-term data.
Other options include open Burch col-
po-suspension, retropubic (top-down 
approach), or the transobturator ap-
proach. Note that the transobturator ap-
proach is limited by the lack of long-
term data.
The use of intramural bulking agents is 
limited by:
• need for repeat injections
• diminishing efficacy with time
• inferior to the retropubic sling
Anterior colporaphy, needle suspen-
sions and para-vaginal defect repair 
are not recommended for the treatment 
of stress incontinence.
Surgery should be performed by sur-
geons with appropriate training. For 
maintaining competence it is suggest-
ed that an annual workload of at least 
20 cases of each primary procedure for 
stress incontinence be performed.
Surgeons should audit their data and 
submit their outcomes to national reg-
istories.
Overactive bladder:
For urinary incontinence, due to detrusor 
over activity, not responding to conser-





Side-effects Most commonly prescribed drug
Often not continued due to side-effects
Slow release oxybutynin Has good efficacy
M3 predominant
While side-effects are 
reduced and therefore 
more acceptable side-ef-
fects still limit use
Single day dosing easier for many patients
Oxybutynin patches Avoids conventional side-ef-
fects while maintaining ef-
ficacy
Patch irritation in 15% Offers new option -patient may prefer 
patches to tablets
Tolterodine Available as bd or ER prepara-
tions
Tends toward bladder speci-
ficity
Fewer side-effects than 
oxybutynin but not as ef-
fective
Developed from terodoline, but associated 
with torsades de pointes.
Withdrawn in early 1990’s




cholinergic gives rise to 
side-effects




STAR study - some advan-
tages over detrusitol
Constipation in some 
patients
May change from second-line to first-line 
choice for many secondary care clinicians
Darifenacin Most M3 selective medication Side effects Recently launched in RSA
Table 2: Comparison of the different drugs used in the treatment of overactive bladder
Adapted from Textbook of female urology and urogynaecology. Staskin S, Cardozo L.2006
vative treatment or drug therapy, sacral 
nerve stimulation may be offered.
Other options include augmentation 
cytoplast in patients willing and able to 
catheterise.
The use of botulinum toxin A in 
patients with idiopathic detrusor over 
activity is limited by the lack of long-
term data. The above treatments may 
be available at selected specialised 
centers.
It is quality of life assessment
important to evaluate the efficacy of 
a particular therapy and compare 
symptom severity between patients by 
measuring the quality of life in women 
with pelvic floor disorders. This can 
be done using the short forms of the 
Pelvic Floor Distress Inventory-20 and 
Pelvic Floor Impact Questionnaire - 7.14 
These are valid, reliable and useful in 
clinical practice. There are many other 
questionnaires available, both generic 
(which lack sensitivity) and disease 
specific e.g. Kings Health Question-
naire.
Conclusion
Urinary incontinence is an important 
public health issue. Epidemiological 
data for South Africa is lacking. This 
may be due to patient factors, lack 
of community continence centres, 
competing health needs, etc. Effective 
non-pharmacological, pharmacologi-
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cal and surgical treatments exist. Only 
by fully understanding the impact of 
urinary incontinence on quality of life 
of women can we hope to improve its 
treatment. 
See CPD Questionnaire, page 43
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